临床儿科杂志 ›› 2018, Vol. 36 ›› Issue (8): 639-.doi: 10.3969/j.issn.1000-3606.2018.08.018
• 文献综述 • 上一篇 下一篇
赵旸综述, 陆爱东, 张乐萍审校
收稿日期:
出版日期:
发布日期:
Reviewer: ZHAO Yang, Reviser: LU Aidong, ZHANG Aiping
Received:
Published:
Online:
摘要： 儿童急性淋巴细胞白血病虽已取得显著疗效，但一旦出现复发或难治，其长期存活机会极少，预后不良。随 着人们对儿童复发难治急性淋巴细胞白血病的分子生物学机制的深入认识，靶向治疗、免疫治疗等新的疗法被用于临床， 且已取得较好的临床效果。文章就儿童难治复发急性淋巴细胞白血病的新疗法进行综述。
Abstract: Nowdays, the curability of childhood acute lymphoblastic leukemia(ALL) has improved dramatically. However, the subgroup of children with refractory/relapsed ALL still presents a dismal prognosis. New trials such as targeted therapy and immunotherapy are used in practice based on a better genomic characterization, and good clinical effect has been achieved. In this article, we review the current new treatments of childhood refractory/relapsed ALL.
赵旸. 儿童难治复发急性淋巴细胞白血病的新治疗策略#br#[J]. 临床儿科杂志, 2018, 36(8): 639-.
ZHAO Yang. New therapy of childhood refractory/relapsed acute lymphoblastic leukemia[J]. , 2018, 36(8): 639-.
推荐
导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks
链接本文: https://jcp.xinhuamed.com.cn/CN/10.3969/j.issn.1000-3606.2018.08.018
https://jcp.xinhuamed.com.cn/CN/Y2018/V36/I8/639
Cited
沪公网安备 31011002000392号
